Mu Cheng, MPH

Analysis Group, Inc., Boston, MA, USA

Poster(s):

• (070) NALIRIFOX versus FOLFOX as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall (OS) survival analysis
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (305) High Misclassification of Glycogen Storage Disease Type 1a in a US Electronic Medical Records Database – Insights from a Physician Note Review
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST

• (342) Final Results from Post-Emergency Use Authorization (EUA) Active Safety Surveillance Study among Individuals in the Veterans Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST